Risk Factors for Ganciclovir-Induced Thrombocytopenia and Leukopenia-Reference-Cited by-同舟云学术

Risk Factors for Ganciclovir-Induced Thrombocytopenia and Leukopenia

Published:2015 Issue:2 Volume:38 Page:235-238
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Matsumoto Kazuaki¹,Shigemi Akari¹,Ikawa Kazuro²,Kanazawa Naoko¹,Fujisaki Yuko¹,Morikawa Norifumi²,Takeda Yasuo¹

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University

2. Department of Clinical Pharmacotherapy, Hiroshima University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/38/2/38_b14-00588/_pdf

Reference17 articles.

1. 1) McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs, 61, 1153–1183 (2001).

2. 2) Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR, Bowden RA. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol. Blood Marrow Transplant., 4, 13–19 (1998).

3. 3) Pescovitz MD, Pruett TL, Gonwa T, Brook B, McGory R, Wicker K, Griffy K, Robinson CA, Jung D. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation, 66, 1104–1107 (1998).

4. 4) Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A. Forscarnet vs. ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant., 22, 175–180 (1998).

5. 5) Gane E, Saliba F, Valdecasas GJ, O’Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet, 350, 1729–1733 (1997).

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus Infection of the Gastrointestinal Tract in Patients on Hemodialysis: A Case Report and Literature Review;Cureus;2024-07-09

2. Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults;British Journal of Clinical Pharmacology;2024-06-18

3. Development and Validation of a Nomogram for Predicting Drug-induced thrombocytopenia in Hospitalized Patients: A Case‒Control Study Based on Propensity-Score Matching;2023-05-24

4. Detecting Donor-Derived DNA by Real-Time PCR in Recipients Suspected of Graft-Versus-Host-Diseases After Liver Transplantation: A Case Series and Literature Review;Annals of Transplantation;2023-02-14

5. Cytomegalovirus Diseases in Hematopoietic Cell Transplant Recipients;Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation;2023